Synovial concentrations of the angiogenic peptides bFGF and VEGF do not discriminate rheumatoid arthritis from other forms of inflammatory arthritis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 64, Issue 1, 2004, Pages 9-16

  Gudbjornsson B ^a   Christofferson, R ^b   Larsson, A ^b  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis factor; Basic fibroblast growth factor; ELISA; Intercellular signalling peptides and proteins; Rheumatoid arthritis; Synovial fluid; Vascular endothelial growth factor

Indexed keywords

ANTIRHEUMATIC AGENT; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; STEROID; VASCULOTROPIN;

ADULT; AGED; ARTHRITIS; ARTICLE; ASPIRATION; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

EID: 10744222202     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510410003732     Document Type: Article

References (30)

1. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-7.
2. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel NA, Liotta LA, editors. The molecular basis of cancer. Philadelphia: WB Saunders; 1995. p. 206-32
3. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31.
5. Senger DR. Molecular framework for angiogenesis. Am J Pathol 1996; 149: 1-7.
6. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987; 8: 95-114.
7. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
8. Qu Z, Huang XN, Ahmadi P, Andresevic J, Planck SR, Hart CE, Rosenbaum JT. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest 1995; 73: 339-46.
9. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180: 341-6.
10. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152: 4149-56.
11. Nagashima M, Yoshino S, Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995; 22: 1624-30.
12. Moses MA, Sudhalter J, Lancer R. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol 1992; 119: 475-82.
13. Koch AE, Burrows JC, Polverini PJ, Cho M, Leibovich SJ. Thiol-containing compounds inhibit the production of monocyte/macrophage-derived angiogenic activity. Agents Actions 1991; 34: 350-7.
14. Billington DC. Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic disorders. Drug Des Discov 1991; 8: 3-35.
15. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992; 175: 1135-8.
16. Oliver SJ, Chena TP, Banqueriao ML, Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol 1995; 166: 196-206.
17. Yamashita A, Yonemitsu Y, Okano S, Nakagawa K, Nakashima Y, Irisa T, Iwamoto Y, Nagai Y, Hasegawa M, Sueishi K. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 2002; 168: 450-7.
18. Sone H, Sakauchi M, Takahashi A, Suzuki H, Inoue N, Iida K, Shimano H, Toyoshima H, Kawakami Y, Okuda Y, Matsuo K, Yamada N. Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life Sci 2001; 69: 1861-9.
19. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, Paleolog EM. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001; 44: 2055-64.
20. Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, Cho CS, Kim HY. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001; 19: 321-4.
21. Brenchley PE. Antagonising angiogenesis in rheumatoid arthritis. Ann Rheum Dis 2001; 60 Suppl 3: iii71-4.
22. de Bandt M, Grossin M, Weber AJ, Chopin M, Elbim C, Pla M, Gougerot-Pocidalo MA, Gaudry M. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 2000; 43: 2056-63.
23. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000; 80: 1195-205.
24. Sone H, Kawakami Y, Sakauchi M, Nakamura Y, Takahashi A, Shimano H, Okuda Y, Segawa T, Suzuki H, Yamada N. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 2001; 281: 562-8.
25. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999; 103: 47-54.
26. Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RH. Quantitation and physiological characterization of angiogenic vessels in mice. Am J Pathol 1996; 149: 59-71.
27. Barleon B, Hauser S, Schollmann C, Weindel K, Marme D, Yayon A, Weich HA. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J Cell Biochem 1994; 54: 56-66.
28. Marme D. Tumor angiogenesis: pivotal role of vascular endothelial growth factor. World J Urol 1996; 14: 166-74.
29. Schreiber L. The endothelium in rheumatoid arthritis. In: Klippel JH, Dieppe PA, editors. Rheumatology. St. Louis: Mosby; 1994. p. 101-6
30. Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, Ariyoshi M, Saiki T, Sakamoto M, Nagata K, Sata M, Matsuo K, Tanikawa K. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27: 377-80.